Literature DB >> 2355142

Anticardiolipin antibodies in Behçet's disease.

R Bergman1, M Lorber, M Lerner, R Brik, R Friedman-Birnbaum.   

Abstract

Twenty-six patients with Behçet's disease were studied for serum levels of anticardiolipin (ACL) antibody isotypes IgG and IgM. The frequency of elevated levels of ACL antibody isotype IgM was found to be significantly increased in these patients. This increased frequency, however, did not correlate statistically with a thrombotic tendency, colchicine intake, antinuclear antibodies, or a positive VDRL test.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2355142     DOI: 10.1111/j.1346-8138.1990.tb01619.x

Source DB:  PubMed          Journal:  J Dermatol        ISSN: 0385-2407            Impact factor:   4.005


  6 in total

Review 1.  Behçet's disease and thrombophilia.

Authors:  M Leiba; Y Sidi; H Gur; A Leiba; M Ehrenfeld
Journal:  Ann Rheum Dis       Date:  2001-12       Impact factor: 19.103

Review 2.  Anticardiolipin (aCL) antibodies in a patient with Behçet's syndrome with vena cava inferior thrombosis.

Authors:  D G Ebo; P G Bracke; L S De Clerck; L M Francx; W J Stevens
Journal:  Clin Rheumatol       Date:  1997-01       Impact factor: 2.980

3.  Fever, haemoptysis and a mass in the heart.

Authors:  M J Steward; D P D'Cruz; L Lang-Lazdunski; J Chambers
Journal:  J R Soc Med       Date:  2007-02       Impact factor: 5.344

4.  Absence of antiphospholipid antibodies in Behçet's disease.

Authors:  M Karmochkine; M C Boffa; B Wechsler; J C Piette; P Godeau
Journal:  Ann Rheum Dis       Date:  1993-08       Impact factor: 19.103

5.  Life-threatening right ventricular thrombosis in association with phospholipid antibodies.

Authors:  S O'Hickey; C Skinner; J Beattie
Journal:  Br Heart J       Date:  1993-09

6.  Prevalence of antiphospholipid antibodies in Behçet's disease: A systematic review and meta-analysis.

Authors:  Md Asiful Islam; Sayeda Sadia Alam; Shoumik Kundu; A H M Safayet Ullah Prodhan; Shahad Saif Khandker; Tatiana Reshetnyak; Przemysław J Kotyla; Rosline Hassan; Tareq Hossan
Journal:  PLoS One       Date:  2020-01-13       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.